Use of Anticoagulants and Recurrent Ischemic Stroke Despite Severe Thrombocytopenia: A Rare Case Presentation
Yıl 2025,
Cilt: 10 Sayı: 3, 99 - 101, 31.12.2025
Nazmiye Serap Biçer
,
Hilal Sipahioğlu
,
Sümeyra Koyuncu
,
Bengisu Gedikli
Öz
This case report examines a rare patient who experienced recurrent ischemic stroke despite severe thrombocytopenia and the use of anticoagulant therapy. The patient's clinical course was characterized by recurrent ischemic events despite the bleeding risks associated with thrombocytopenia. Diagnostic evaluations and the treatment process are discussed, highlighting the clinical management challenges in such complex cases. The emphasis is placed on the use and safety of anticoagulant therapy and strategies for managing ischemic stroke in patients with hematologic abnormalities. She was investigated for thrombocytopenia presented in her admission and given corticosteroid therapy for suspected idiopathic thrombocytopenic purpura (ITP), which did not respond, but her thrombocytopenia was corrected with eltrombopag therapy, and she was successfully managed with antiaggregant anticoagulant therapy.
Etik Beyan
Onam alınmıştır.
Destekleyen Kurum
yoktur.
Teşekkür
Katkı sağlayan tüm yazarlara teşekkürlerimizi sunarız.
Kaynakça
-
1. Jinna S, Khandhar PB. Thrombocytopenia. In: StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Jul 3].
Available from: https://www.ncbi.nlm.nih.gov/books/NBK537065/.
-
2. Tufano A, Brenner B. Prevention of venous thromboembolism in
medical patients with thrombocytopenia or with platelet dysfunction:
the last 10 years. Semin Thromb Hemost. 2024;50(1):96–103.
-
3. Guntu R, Patel A, Movahed MR, Hashemzadeh M, Hashemzadeh
M. Association between idiopathic thrombocytopenic purpura
and hemorrhagic and nonhemorrhagic stroke. Crit Pathw Cardiol.
2024;23(1):26–29.
-
4. Uzun G, Zlamal J, Althaus K, Bevot A, Hennersdorf F, Wolska N, et
al. Cerebral venous sinus thrombosis and thrombocytopenia due to
heparin-independent anti-PF4 antibodies after adenovirus infection.
Haematologica. 2024;109(6):2010–2015.
-
5. Xu Y, Liu C, Zhou Q, Gu H, Jia Y, Meng D, et al. Thrombocytopenia
and in-hospital outcomes in patients with acute ischemic
stroke undergoing intravenous thrombolysis: findings from a
nationwide registry study in China. J Stroke Cerebrovasc Dis.
2024;33(8):107805.
-
6. Xu D, Zhou H, Hu M, Shen Y, Li H, Wei L, et al. Safety of early
antiplatelet therapy for non-cardioembolic mild stroke patients
with thrombocytopenia. Zhejiang Da Xue Xue Bao Yi Xue Ban.
2024;53(2):175–183.
-
7. Mahadevan JJ, Psaltis PJ, Thrift AG, Kleinig TJ. Incidence of
thrombocytopenia-associated cerebral venous sinus thrombosis: a
population-based study. BMJ Neurol Open. 2024;6(1): e000605.
-
8. Yalçin E, Yalçin M, Çelik Y, Ekuklu G. Risk factors for recurrent
ischemic stroke in Turkey. Trakya Universitesi Tip Fakultesi
Dergisi. 2008;25(2): 117.
Ciddi Trombositopeniye Rağmen Antikoagülan Kullanımı ve Tekrarlayan İskemik İnme: Nadir Bir Olgu Sunumu
Yıl 2025,
Cilt: 10 Sayı: 3, 99 - 101, 31.12.2025
Nazmiye Serap Biçer
,
Hilal Sipahioğlu
,
Sümeyra Koyuncu
,
Bengisu Gedikli
Öz
Bu olgu sunumu, ciddi trombositopeniye ve devam eden antikoagülan tedaviye rağmen tekrarlayan iskemik inme geçiren nadir bir hastayı ele almaktadır. Hastanın klinik seyri, trombositopeniye bağlı kanama riskine karşın gelişen tekrarlayan iskemik olaylarla karakterizedir. Tanısal değerlendirmeler ve tedavi süreci ayrıntılı olarak sunulmakta; bu tür karmaşık klinik olgularda yönetim stratejilerinin zorluklarına vurgu yapılmaktadır. Özellikle hematolojik bozukluklara sahip hastalarda antikoagülan tedavi kullanımı ve güvenliği ile iskemik inmeye yaklaşım stratejileri ön plana çıkarılmıştır. Başvuru sırasında tespit edilen trombositopeni nedeniyle hastaya öncelikle idiyopatik trombositopenik purpura (ITP) ön tanısıyla kortikosteroid tedavisi başlanmış; ancak klinik yanıt alınamamıştır. Daha sonra eltrombopag tedavisine geçilmiş ve trombositopeni bu tedaviyle düzeltilmiştir. Bu gelişmelerin ardından hasta antiagregan ve antikoagülan tedaviyle güvenli şekilde izlenmiş ve başarılı bir şekilde yönetilmiştir. Bu vaka, hematolojik bozukluklara rağmen bireyselleştirilmiş tedavi yaklaşımlarıyla iskemik inme yönetiminin nasıl güvenli biçimde uygulanabileceğine dair özgün bulgular sunmaktadır.
Kaynakça
-
1. Jinna S, Khandhar PB. Thrombocytopenia. In: StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Jul 3].
Available from: https://www.ncbi.nlm.nih.gov/books/NBK537065/.
-
2. Tufano A, Brenner B. Prevention of venous thromboembolism in
medical patients with thrombocytopenia or with platelet dysfunction:
the last 10 years. Semin Thromb Hemost. 2024;50(1):96–103.
-
3. Guntu R, Patel A, Movahed MR, Hashemzadeh M, Hashemzadeh
M. Association between idiopathic thrombocytopenic purpura
and hemorrhagic and nonhemorrhagic stroke. Crit Pathw Cardiol.
2024;23(1):26–29.
-
4. Uzun G, Zlamal J, Althaus K, Bevot A, Hennersdorf F, Wolska N, et
al. Cerebral venous sinus thrombosis and thrombocytopenia due to
heparin-independent anti-PF4 antibodies after adenovirus infection.
Haematologica. 2024;109(6):2010–2015.
-
5. Xu Y, Liu C, Zhou Q, Gu H, Jia Y, Meng D, et al. Thrombocytopenia
and in-hospital outcomes in patients with acute ischemic
stroke undergoing intravenous thrombolysis: findings from a
nationwide registry study in China. J Stroke Cerebrovasc Dis.
2024;33(8):107805.
-
6. Xu D, Zhou H, Hu M, Shen Y, Li H, Wei L, et al. Safety of early
antiplatelet therapy for non-cardioembolic mild stroke patients
with thrombocytopenia. Zhejiang Da Xue Xue Bao Yi Xue Ban.
2024;53(2):175–183.
-
7. Mahadevan JJ, Psaltis PJ, Thrift AG, Kleinig TJ. Incidence of
thrombocytopenia-associated cerebral venous sinus thrombosis: a
population-based study. BMJ Neurol Open. 2024;6(1): e000605.
-
8. Yalçin E, Yalçin M, Çelik Y, Ekuklu G. Risk factors for recurrent
ischemic stroke in Turkey. Trakya Universitesi Tip Fakultesi
Dergisi. 2008;25(2): 117.